Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic responds to FDA warning on CRDM division

This article was originally published in Clinica

Executive Summary

The US FDA has sent Medtronic a warning letter after an inspection of the company's cardiac rhythm disease management (CRDM) operations in Minnesota in August raised a number of concerns. The issues are related to Medtronic's procedures for identifying, preventing and correcting problems with CRDM devices; the company's timeliness for reporting these problems to the FDA; the documentation of the field action; and quality control of suppliers. Medtronic had to recall around 34,000 pacemakers in May due to potential wiring defects (, June 12 2009).The firm said on Wednesday (November 18) that it will respond to the warning letter within 15 days, as required. It added that it has started to implement changes, and that the FDA had noted the company's efforts in its warning letter and deemed them "adequate". This is not the first time that the agency has criticised the top medtech manufacturer over its tardy response to product recalls – in June, the FDA revealed that the company took over two years to issue a recall of faulty drug and insulin pumps (, June 29 2009).

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts